Bristol-Myers Squibb said it will buy diabetes drug maker Amylin in a $7 billion deal that will intensify the competition to treat the growing number of people afflicted with the disease.
Bristol-Myers Squibb said it will buy diabetes drug maker Amylin in a $7 billion deal that will intensify the competition to treat the growing number of people afflicted with the disease.